Targeted immunotherapy in acute myeloid leukemia (AML) is challenged by the lack of AML-
specific target antigens and clonal heterogeneity, leading to unwanted on-target off …

Recent major advances in understanding the molecular basis of acute myeloid leukemia
(AML) provide a double-edged sword. Although defining the topology and key features of …

Background Gemtuzumab ozogamicin was the first example of antibody-directed
chemotherapy in cancer, and was developed for acute myeloid leukaemia. However …

Because the outcome of allogeneic hematopoietic cell transplantation (HCT) is
predominantly influenced by disease type and status, it is essential to be able to stratify …

PURPOSE Reduced-intensity conditioning (RIC) regimens have extended the curative
potential of allogeneic stem-cell transplantation to older adults with high-risk acute myeloid …

The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in
rapid translation of the information into clinical practice. After more than 40 years of slow …

Acute myeloid leukaemia (AML) is a disorder characterized by a clonal proliferation derived
from primitive haematopoietic stem cells or progenitor cells. Abnormal differentiation of …

Purpose Patients with acute myeloid leukemia (AML) who are in morphologic complete
remission are typically considered separately from patients with active disease (ie,≥ 5 …

Genomic analysis has greatly influenced the diagnosis and clinical management of patients
affected by diverse forms of hematologic malignancies. Here, we review how genetic …

The outlook for patients with acute myeloid leukaemia has improved in the past 30 years.
Unlike other cancers, much of this progress is attributable to refinement of supportive …